CLOSEOUT LETTER
N.V.E. Pharmaceuticals, Inc.
- Recipient:
- N.V.E. Pharmaceuticals, Inc.
United States
- Issuing Office:
United States
Department of Health and Human Services | Public Health Service Food and Drug Administration |
New Jersey District Office Central Region Waterview Corporate Center 10 Waterview Blvd. 3rd Floor Parsippany, New Jersey 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 |
February 21, 2017
Mr. Robert Occhifinto, President and Owner
NVE Pharmaceuticals, Inc.
15 Whitehall Road
Andover, New Jersey 07821
Dear Mr Occhifinto:
The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter, file number 13-NWJ-11. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Stephanie Durso
Acting Director of Compliance
New Jersey District